Reyvow Tablet
Product Images NDC 0002-4491
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Reyvow (NDC 0002-4491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Reyvow 50mg 8ct 040 01
Figure 1 (Reyvow Uspi 1 V1)
This appears to be a graph showing the percentage of people achieving migraine pain freedom over time after taking different doses of a medication called REYVOW, as well as a placebo. The doses shown are 50mg, 100mg, and 200mg. The graph shows that a higher percentage of people achieved migraine pain freedom with REYVOW compared to the placebo, with the 200mg dose appearing to be the most effective. The time frame shown on the graph ranges from 0 to 2 hours after taking the medication.*
Figure 2 (Reyvow Uspi 2 V1)
The text appears to be a chart displaying the percentage of individuals achieving "MBS freedom" at various time points after taking different doses of a drug called "REYVOW" or a placebo. The drug is available in 50mg, 100mg, and 200mg doses. However, the meaning of "MBS freedom" and any additional information about the drug or study are not available.*
Structural Formula (Reyvow Uspi Chem V1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.